



June 22nd, 2016

ViperGen enters into multi-target drug discovery agreement with Daiichi Sankyo

Copenhagen, Denmark, June 22nd, 2016 - - ViperGen ApS announced today the signing of a multi-target drug discovery agreement with Daiichi Sankyo Co., Ltd. (hereinafter “Daiichi Sankyo”). Under the terms of the agreement, ViperGen’s small molecule discovery engine, a proprietary high fidelity DNA-encoded library technology platform, will be applied across therapeutic projects to identify novel hits/leads for selected targets from Daiichi Sankyo. Daiichi Sankyo obtains exclusive options to selected hits/leads and hit/lead series. The therapeutic areas of the targets were not disclosed. No information about the financial arrangement was provided.

“We are very proud to be selected by Daiichi Sankyo, a global industry leader in drug discovery and development.” said Nils Hansen, Chief Executive Officer of ViperGen. “ViperGen has designed and implemented its discovery engine to deliver high quality hits and leads for very challenging but important protein targets as Daiichi Sankyo is tackling to address unmet medical needs. We look forward to working with Daiichi Sankyo.”

About Daiichi Sankyo Company

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets. With over 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo research and development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney diseases, and other rare diseases. For more information, please visit: www.daiichisankyo.com.

About ViperGen ApS

ViperGen is dedicated to small molecule drug discovery using DNA-encoded library platforms.

ViperGen leverages its innovative and proprietary drug discovery platforms in partnerships with leading pharmaceutical and biotech companies.

ViperGen’s two 2nd generation technology platforms - The YoctoReactor[®] for synthesizing DNA-encoded chemical libraries and Binder Trap Enrichment[®] for screening of such libraries - are designed to deliver high fidelity drug discovery.

For further details about ViperGen and the YoctoReactor[®] / Binder Trap Enrichment[®] drug discovery technology platforms please visit www.viperGen.com or contact:

ViperGen ApS
Dr. Nils Hansen,
Chief Executive Officer
Phone: +45 2523 6680
nha@viperGen.com